360 related articles for article (PubMed ID: 10999043)
1. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
[TBL] [Abstract][Full Text] [Related]
2. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
4. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
5. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers.
Yeh KH; Cheng AL; Lin MT; Hong RL; Hsu CH; Lin JF; Chang KJ; Lee PH; Chen YC
Anticancer Res; 1997; 17(5B):3867-71. PubMed ID: 9427794
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
Grem JL
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
10. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
Parulekar W; de Marsh RW; Wong R; Mendenhall W; Davey P; Zlotecki R; Berry S; Rout WR; Bjarnason GA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1487-95. PubMed ID: 15050328
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
14. A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
Meropol NJ; Petrelli NJ; Rustum YM; Rodriguez-Bigas M; Blumenson LE; Frank C; Berghorn E; Creaven PJ
Invest New Drugs; 1995; 13(2):149-55. PubMed ID: 8617578
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Marshall JL; Richmond E; DeLap RJ
Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
[TBL] [Abstract][Full Text] [Related]
18. A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors.
Souglakos J; Kakolyris S; Vardakis N; Androulakis N; Mavroudis D; Vamvakas L; Kouroussis C; Agelaki S; Saridaki Z; Georgoulias V
Cancer Invest; 2005; 23(6):505-10. PubMed ID: 16203658
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]